Previous 10 | Next 10 |
-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Ended Quarter with $52.4 million in Cash; Sufficient for Funding Operations into 2Q 2024 -- ARLINGTON, Mass., Nov. 08, 2022 (GL...
ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare disea...
Kala Pharmaceuticals ( NASDAQ: KALA ) will implement a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares, effective at 4:05 p.m. on October 20, 2022. Every 50 shares of Kala’s ( KALA ) issued and outstanding c...
ARLINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare disea...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time for another look at the biggest pre-market stock movers as we check out what’s happening Tuesday morning! Moving stocks this morning are heavy trading, acqui...
The following slide deck was published by Kala Pharmaceuticals, Inc. in conjunction with this event. For further details see: Kala Pharrmaceuticals Investor Presentation - Slideshow
ARLINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will present a...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time for another breakdown of the biggest pre-market stock movers and the news moving them on Wednesday! We’ve got a SPAC merger, special shareholder meetings, st...
Kala Pharmaceuticals, Inc. (KALA) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Hannah Deresiewicz – Stern Investor Relations Mark Iwicki – Chief Executive Officer Kim Brazzell – Head-R&D and Chief Medic...
The following slide deck was published by Kala Pharmaceuticals, Inc. in conjunction with this event. For further details see: Kala Pharmaceuticals (KALA) Investor Presentation (Slideshow)
News, Short Squeeze, Breakout and More Instantly...
Kala Pharmaceuticals Inc. Company Name:
KALA Stock Symbol:
NASDAQ Market:
Kala Pharmaceuticals Inc. Website:
2024-07-27 11:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is one of today's top gainers. The company's shares have moved 44.91% on the day to $6.55. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus pe...